Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript

Core Viewpoint - Theravance Biopharma is focusing on ampreloxetine, an orphan drug aimed at treating neurogenic orthostatic hypotension in patients with multiple system atrophy, with pivotal Phase III study data expected in Q1 2026 [2][3]. Group 1: Product Overview - Ampreloxetine is designed to address a significant unmet need in symptomatic neurogenic orthostatic hypotension (nOH) [3]. - The drug is positioned as a once-daily oral medication that offers a durable treatment effect, potentially transforming the treatment landscape for affected patients [3]. Group 2: Clinical Development - The pivotal Phase III study, named CYPRESS, is nearing completion, with results anticipated in the first quarter of 2026 [2].